Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,390 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High numbers of programmed cell death-1-positive tumor infiltrating lymphocytes correlate with early onset of post-transplant lymphoproliferative disorder.
Saito H, Miyoshi H, Shibayama H, Toda J, Kusakabe S, Ichii M, Fujita J, Fukushima K, Maeda T, Mizuki M, Oritani K, Seto M, Yokota T, Kanakura Y, Hosen N, Ohshima K. Saito H, et al. Among authors: fujita j. Int J Hematol. 2021 Jul;114(1):53-64. doi: 10.1007/s12185-021-03129-3. Epub 2021 Mar 25. Int J Hematol. 2021. PMID: 33765256
Autoimmune-mediated thrombocytopenia after allogeneic hematopoietic stem cell transplantation: significance of detecting reticulated platelets and glycoprotein-specific platelet autoantibodies.
Akuta K, Fukushima K, Nakata K, Hayashi S, Toda J, Shingai Y, Tsutsumi K, Machida T, Hino A, Kusakabe S, Doi Y, Fujita J, Kato H, Maeda T, Yokota T, Tomiyama Y, Hosen N, Kashiwagi H. Akuta K, et al. Among authors: fujita j. Int J Hematol. 2022 Mar;115(3):322-328. doi: 10.1007/s12185-021-03272-x. Epub 2022 Jan 17. Int J Hematol. 2022. PMID: 35037230
Addition of melphalan to fludarabine/busulfan (FLU/BU4/MEL) provides survival benefit for patients with myeloid malignancy following allogeneic bone-marrow transplantation/peripheral blood stem-cell transplantation.
Ueda T, Maeda T, Kusakabe S, Fujita J, Fukushima K, Yokota T, Shibayama H, Tomiyama Y, Kanakura Y. Ueda T, et al. Among authors: fujita j. Int J Hematol. 2019 Feb;109(2):197-205. doi: 10.1007/s12185-018-2562-8. Epub 2018 Nov 17. Int J Hematol. 2019. PMID: 30448938
Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ueda T, Fukushima K, Kusakabe S, Yoshida K, Suga M, Nakai R, Koike M, Hino A, Akuta K, Toda J, Nagate Y, Doi Y, Fujita J, Yokota T, Hosen N. Ueda T, et al. Among authors: fujita j. Leuk Res Rep. 2022 Feb 15;17:100294. doi: 10.1016/j.lrr.2022.100294. eCollection 2022. Leuk Res Rep. 2022. PMID: 35242526 Free PMC article.
1,390 results